Flare on serial prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT examinations in castration-resistant prostate cancer: First observations

Katherine A. Zukotynski, John Valliant, François Bénard, Steven P. Rowe, Chun K. Kim, Martin G. Pomper, Steve Y. Cho

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

A 71-year-old man with castration-resistant prostate cancer demonstrated a flare phenomenon on 99mTc-MDP and CT after 10 weeks of enzalutamide. Prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT demonstrated minimal uptake at sites of baseline bone and lymph node disease with increasing uptake at sites of osseous disease following therapy. Although this is likely related in part to decreased androgen receptor activity and a consequent increase in prostate-specific membrane antigen expression, other mechanisms (neovascularization, cell infiltration from the bone repair process, osteoblastic turnover, or minimal radiotracer impurity) may also be involved in causing the increased 18F-DCFPyL uptake at sites of osseous flare.

Original languageEnglish
Pages (from-to)213-216
Number of pages4
JournalClinical Nuclear Medicine
Volume43
Issue number3
DOIs
StatePublished - 2018 Mar

Keywords

  • F-DCFPyL
  • PET/CT
  • PSMA
  • Prostate cancer

Fingerprint Dive into the research topics of 'Flare on serial prostate-specific membrane antigen-targeted <sup>18</sup>F-DCFPyL PET/CT examinations in castration-resistant prostate cancer: First observations'. Together they form a unique fingerprint.

  • Cite this